Quest Diagnostics Highlights Growth Strategy at Healthcare Conference

Quest Diagnostics ( (DGX) ) has shared an update.

On January 12, 2026, Quest Diagnostics outlined its growth strategy and operational priorities at the 44th Annual J.P. Morgan Healthcare Conference, emphasizing its role in an approximately $89 billion U.S. lab market and a roughly $5 billion Canadian lab market. Management detailed plans for above-market revenue growth by deepening penetration in physician and hospital channels, expanding Collaborative Lab Solutions and outreach arrangements, and leveraging its scale and technology to meet rising demand from enterprise healthcare customers. The company highlighted high-growth areas such as consumer-initiated testing, partnerships in the wellness ecosystem, and advanced diagnostics across cardiometabolic health, autoimmune disease, brain health, oncology, and women’s and reproductive health, with these specialty tests projected to approach $1 billion in revenue in 2025. Quest also stressed ongoing productivity and cost-savings initiatives, including automation and AI across lab and logistics operations, which are improving efficiency and customer satisfaction and are central to its strategy to drive sustainable growth and long-term value for stakeholders.

The most recent analyst rating on (DGX) stock is a Hold with a $195.00 price target. To see the full list of analyst forecasts on Quest Diagnostics stock, see the DGX Stock Forecast page.

Spark’s Take on DGX Stock

According to Spark, TipRanks’ AI Analyst, DGX is a Outperform.

Quest Diagnostics receives a strong overall score driven by robust financial performance, positive technical indicators, and a favorable earnings call. The company’s strategic focus on acquisitions and advanced diagnostics supports its growth potential. While valuation is fair, the raised guidance and successful collaborations enhance investor confidence.

To see Spark’s full report on DGX stock, click here.

More about Quest Diagnostics

Quest Diagnostics is a leading provider of clinical laboratory testing and diagnostic information services, positioned at the center of the U.S. healthcare system with about half of U.S. hospitals and physicians and roughly one-third of U.S. adults served annually. The company operates around 8,000 patient access sites, a large logistics network, and extensive data assets exceeding 80 billion patient data points, while also expanding internationally through LifeLabs in Canada, where it is a leading provider in a roughly $5 billion lab market.

Average Trading Volume: 1,068,974

Technical Sentiment Signal: Buy

Current Market Cap: $19.77B

See more insights into DGX stock on TipRanks’ Stock Analysis page.